GHRP-2 vs GHRP-6

These two molecules are siblings in the original GHRP series and the comparison reads most cleanly on three axes: GH-release potency, appetite stimulus, and downstream hormone movement. GHRP-2 is the more potent GH releaser at equivalent per-dose milligrams; GHRP-6 produces the larger appetite signal. Both move cortisol and prolactin a meaningful amount in published work, which is the structural reason later-generation peptides like ipamorelin were designed.

In a log the two molecules occupy slightly different roles. GHRP-2 logs tend to focus on the GH endpoint and the small downstream hormone-pattern proxies that go with it (sleep quality, morning energy, fasting glucose nudges). GHRP-6 logs almost always also include appetite as a tracked variable — the hunger stimulus is too strong to ignore, and reading the rest of the log without it tends to attribute meal-timing artifacts to the peptide itself.

Per-dose milligrams are in the same range — 100–200 mcg per administration is typical for either — and the cadence is also similar at two-to-three administrations a day driven by short half-lives. The unit math on a 100-unit syringe at the same vial concentration lands in the same neighborhood for both. The vial-duration calculator linked below shows how the slight per-dose difference between the two molecules plays out across a month at typical cadences.

Stack pairing with a GHRH-side peptide is the same workflow for both: parallel log timelines, never merged. The difference is the appetite field — a CJC-1295 plus GHRP-6 stack benefits from explicit hunger and meal-timing tracking; a CJC-1295 plus GHRP-2 stack usually does not need that field. Reconstitution is identical for both molecules, and the standard 5 mg vial reconstituted with 2 mL of bacteriostatic water hits the same 2.5 mg/mL concentration for either.

For the GHRP-2 vs GHRP-6 decision specifically, the calendar shape is what most readers underweight. GHRP-2's example vial is 5 mg drawn against 0.1 mg per dose at 7 doses per week. GHRP-6's example vial is 5 mg drawn against 0.1 mg per dose at 7 doses per week. Those four numbers feed every column in the table above; change any one and the ghrp 2 vs ghrp 6 comparison shifts with it.

Concentration in this pair: GHRP-2 sits at 2.50 mg/mL on the example reconstitution; GHRP-6 sits at 2.50 mg/mL on its example. That single ratio is what determines how many U-100 syringe units a given dose of either molecule actually draws, so it is the first thing to confirm before treating any "GHRP-2 vs GHRP-6" unit number on the internet as authoritative.

Doses per vial in this matchup work out to roughly 50 for GHRP-2 and 50 for GHRP-6 at the example dose sizes, with vial-duration windows near 7.1 weeks and 7.1 weeks respectively. Refill cadence follows directly from those windows, which is why the ghrp 2 vs ghrp 6 pair shows up in planning conversations more than in pure mechanism conversations.

When readers compare GHRP-2 against GHRP-6, the GHRP-2-side mistakes that show up most in logs are: Mistaking GHRP-2 for GHRP-6 and failing to account for the documented differences in their side-effect profiles regarding appetite stimulation and prolactin. Neglecting to log the specific time of day for each dose in a multi-dose schedule, which renders later analysis of the data almost meaningless. Using a large-volume syringe (e.g., a 3 mL syringe) that lacks the fine gradations needed to accurately measure a typical 100 mcg dose volume. Administering a dose immediately following a large meal, a variable noted in research that can interfere with the peptide's primary action. Each of these gets amplified when a reader is also actively comparing against GHRP-6, because muscle memory from one molecule's unit math leaks into the other.

GHRP-2 question worth answering up front — How is GHRP-2 structurally different from GHRP-6? GHRP-2 is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-D-Trp-D-Phe-Lys-NH2. It was developed as a second-generation evolution of GHRP-6. The primary structural difference is the substitution of the natural L-Alanine found in GHRP-6 with a synthetic D-Alanine residue. This single amino acid change significantly alters the molecule’s interaction with the ghrelin receptor, giving rise to its different selectivity profile.

GHRP-2 question worth answering up front — Why do studies describe GHRP-2 as more selective than GHRP-6? In comparative scientific studies, GHRP-2 has been observed to stimulate a potent release of growth hormone while having a lesser impact on cortisol, prolactin, and appetite compared to dose-equivalent administrations of GHRP-6. This means its action is more focused on GH release. While it targets the same ghrelin receptor, its modified structure results in this more specific downstream effect, though it is still considered less selective than the third-generation peptide ipamorelin.

On the GHRP-6 side of the GHRP-2 vs GHRP-6 decision, the recurring mistakes are: Failing to document the potent hunger response on a consistent scale, mistaking a primary mechanistic effect for an incidental side effect. Interpreting the transient increases in cortisol and prolactin as an unexpected deviation, rather than a well-documented characteristic of this first-generation molecule. Analyzing data on a day-to-day basis instead of observing the aggregate trends in appetite and sleep quality scores over a multi-week timeline. Neglecting to record the administration time relative to meals, which is a crucial variable for contextualizing the peptide's orexigenic impact. These are not generic dosing slips — they are the ones that compound when GHRP-6 is being logged in parallel with GHRP-2.

GHRP-6 question worth answering up front — How does tracking for GHRP-6 differ from tracking for ipamorelin or GHRP-2? The primary distinction is the emphasis on appetite monitoring. A log for ipamorelin would focus almost exclusively on GH-related metrics, whereas a log for GHRP-6 should feature a hunger rating (e.g., on a 1–10 scale) as a primary data field. Because GHRP-6 binds to the ghrelin receptor in a manner that strongly stimulates appetite, this orexigenic effect is a direct part of its mechanism to be observed, not a secondary consideration.

GHRP-6 question worth answering up front — What do historical research studies indicate about cortisol and prolactin with GHRP-6? Scientific literature dating back to the 1980s consistently shows that GHRP-6 administration leads to measurable, dose-dependent increases in plasma cortisol and prolactin. This effect is significantly more pronounced than that observed with its successors, GHRP-2 and ipamorelin. In fact, the desire to reduce these off-target hormonal effects was a major driver behind the development of those later-generation peptides.